drugset
drugset / Trial / NCT04327765

Staccato® Granisetron Multiple Dose PK

NCT04327765 ↗

Phase 1 Completed 30 enrolled Alexza Pharmaceuticals, Inc. Celerion · collab
RandomizedSequentialTriple-blindTreatment

Summary

To examine the tolerability and safety of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers To characterize the pharmacokinetics of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers

Timeline

Start
2020-03-10
Primary completion
2020-08-04
Completion
2020-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AZ-010 Unknown 0.5 mg Inhaled
Subject AZ-010 Unknown 1 mg Inhaled
Subject AZ-010 Unknown 3 mg Inhaled

Indications

No indication recorded.